Australian clinicians hold mixed views on psychedelic-assisted therapy. A survey of mental health professionals found that while many acknowledge potential therapeutic benefits for conditions such as depression and PTSD, concerns remain about safety, regulatory frameworks, and lack of training. The majority supported further research but were cautious about immediate clinical implementation, with attitudes varying by professional background and prior knowledge of psychedelics.
MDMA (Ecstasy) use in early adulthood appears to be associated with higher odds of anxiety disorders by the mid-30s, but not with depressive disorders. Compared with non-users, those who reported past-year MDMA use had 1.73 times the odds of an anxiety disorder; persistent use at two or more waves was linked to 2.05 times the odds, infrequent use to 2.11 times, and frequent use to 2.56 times the odds. These findings come from a longitudinal population-based study in Victoria, Australia, following 1,943 adolescents into their mid-30s.